肝细胞癌的向治疗方法:过去,现在和未来
Rushabh Gujarathi1, Joseph W Franses1, Anjana Pillai2
1Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, United States.
Frontiers in oncology
|September 13, 2024
概括
针对晚期肝细胞癌 (HCC) 的向疗法面临着挑战. 本综述探讨了过去和新的目标,如Wnt/β-catenin,为未来的HCC治疗策略提供了见解.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对性治疗对于晚期,不可切除或转移性肝细胞癌 (HCC) 是至关重要的.
- 以前针对c-Met,TGF-β和FGFR的向药物在HCC中显示出有限的临床益处.
- 尽管过去出现了挫折,但这些目标对于未来的治疗开发仍然很重要.
研究的目的:
- 审查先前在HCC中评估的治疗点.
- 探索HCC治疗的新和新兴目标.
- 在正在进行的和未来的HCC研究中评估这些目标的持续相关性.
主要方法:
- 对针对HCC的向治疗的临床研究的文献综述.
- 对先前评估的目标 (c-Met,TGF-β,FGFR) 的分析.
- 识别和讨论新型目标 (Wnt/β-catenin,c-Myc,GPC3,PPT1) 的研究.
主要成果:
- 已经研究了几种针对HCC的向治疗方法.
- 过去的目标如c-Met,TGF-β和FGFR没有显示出显著的临床益处.
- 包括Wnt/β-catenin通路,c-Myc,GPC3和PPT1在内的新目标正在积极调查中.
结论:
- 虽然过去针对HCC的向疗法取得了有限的成功,但确定的目标仍然很重要.
- 新的目标显示出未来HCC治疗策略的前景.
- 对这些目标的持续研究对于推进HCC治疗至关重要.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.1K
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
713
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K